# Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment

> **NCT05443230** · — · UNKNOWN · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Liver Cancer
- Sarcopenia

## Interventions

- **DIAGNOSTIC_TEST:** gait speed; ct scan; grip strength and chair stand test

## Key facts

- **NCT ID:** NCT05443230
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443230, "Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05443230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*